Complement-C1 inhibitor protein (Octapharma)

N/A

Report date: 2024/05/11 20:00:08

Base Information

Drug NameComplement-C1 inhibitor protein (Octapharma)
Drug Alias NameC1 Esterase inhibitor (Octapharma)OCTA-C1-INHHuman plasma derived C1 Esterase inhibitor (Octapharma)
ClassificationBiologics
Mechanisms of ActionSerine protease hepsin inhibitorsComplement C1s inhibitors
TargetsSerine protease hepsinComplement C1s
Therapy Area/IndicationsAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryArmeniaBulgariaUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOctapharma
China Registration ClassN/A

Develop Information

Active CompaniesOctapharmaOctapharma Ab
Inactive CompaniesN/A
Active IndicationsAngioedemas, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A